Jasper Reports Wider Loss in Fiscal Q2

Jasper Therapeutics (JSPR) reported a Q2 2025 GAAP loss per share of $1.74 with no revenue, while R&D expenses nearly doubled to $21.2 million, depleting cash to $39.5 million and shortening its runway to under two quarters. Despite positive initial clinical data for its lead drug briquilimab in mast cell-driven diseases, the company faces a critical manufacturing inconsistency issue impacting efficacy in some patient cohorts, pushing pivotal study initiation to mid-2026. The firm's immediate future is contingent on resolving this manufacturing challenge and managing its significantly constrained liquidity.

Analysis

Jasper Therapeutics' Q2 2025 financial results reveal a company in a precarious position, defined by a deepening operational loss and a critical cash runway issue. The reported GAAP loss per share of $1.74 significantly missed the ($1.33) estimate and marked a 79.4% decline from the prior year's quarter. This was driven by a near-doubling of R&D expenses to $21.2 million, which has rapidly depleted the company's liquidity. Cash and equivalents have fallen to $39.5 million, providing a runway of less than two quarters at the current burn rate and creating an immediate need for new financing. While the lead drug candidate, briquilimab, has shown compelling initial efficacy with high complete response rates in early trial cohorts for CSU and CIndU (89% and 92% respectively), this clinical promise is severely compromised by a significant manufacturing setback. A failure in a specific drug lot, which resulted in zero efficacy for an entire 10-patient cohort, raises serious concerns about product consistency and CMC (Chemistry, Manufacturing, and Controls) capabilities. This issue has directly caused the delay of the pivotal Phase 2b study start to mid-2026, pushing out key value-inflection milestones. The company's strategic pivot to focus solely on briquilimab, accompanied by a 50% workforce reduction and management changes including the departure of the Chief Medical Officer, underscores the high-stakes, single-asset nature of the current business, where any further setbacks could be existential.

Key Decisions for Investors

• Investors must anticipate a highly dilutive financing event in the near term given the cash runway of less than two quarters, and the terms of any capital raise will be critical to the company's survival.
• The primary focus should be on the late 2025 data release concerning the redosed BEACON trial patients, as failure to resolve the drug lot variability and replicate initial efficacy would represent a catastrophic failure for the briquilimab program.
• Given the combination of a severe liquidity crunch, a critical manufacturing problem delaying the pivotal trial, and management instability, the company's risk profile has increased substantially, warranting a re-evaluation of any existing long positions.
• Monitor for any pre-announcements or updates regarding the manufacturing investigation, as this remains the single largest overhang on the asset's clinical and commercial potential.